Global longitudinal assessment of treatment outcomes in recurrent/metastatic nasopharyngeal carcinoma: GLANCE-NPC study.
| Autor: | Ahn MJ; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 135-710, South Korea., Chirovsky D; Merck & Co., Inc., Kenilworth, NJ 07033, USA., Kuyas H; Kantar Health Division, Paris, 75014, France., Auclair V; Kantar Health Division, Paris, 75014, France., Abounit S; Kantar Health Division, Paris, 75014, France., Joo S; Merck & Co., Inc., Kenilworth, NJ 07033, USA., Shah R; Merck & Co., Inc., Kenilworth, NJ 07033, USA., Yang MH; Department of Medicine, Taipei Veterans General Hospital, Division of Medical Oncology, Taipei, 112, Taiwan. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Future oncology (London, England) [Future Oncol] 2021 Jun; Vol. 17 (16), pp. 2015-2025. Date of Electronic Publication: 2021 Feb 19. |
| DOI: | 10.2217/fon-2020-1087 |
| Abstrakt: | Aim: Given a lack of standard of care treatment for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), we assessed treatment patterns and overall survival in the real-world setting. Materials & methods: A retrospective chart review was conducted in patients who initiated first-line systemic therapy in Taiwan and South Korea between January 2012 and June 2013 with follow-up through December 2015. Results: Among 154 R/M NPC patients, all patients in Taiwan (n = 104) had distant metastases, whereas in South Korea (n = 50) 42% had distant metastases. Patients with distant metastases generally received systemic therapy only (71%) for whom median overall survival was 23 months (95% CI: 18-32). Conclusion: Prognosis in R/M NPC with distant metastases remains poor, underscoring the need for more efficacious treatments. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|